IMMUNOCLIN LIMITED
ActiveCompany number 03914021
London · Incorporated 26 January 2000
2 Royal College Street, London, NW1 0NH
Last updated on 19 September 2026
Manufacture of pharmaceutical preparations · SIC 21200
Technical testing and analysis · SIC 71200
Research and experimental development on biotechnology · SIC 72110
Company history
IMMUNOVA LABORATORIES LIMITED · 26 January 2000 – 22 June 2000
IMMUNOCLIN LABORATORIES LIMITED · 22 June 2000 – 2 August 2002
Company overview
IMMUNOCLIN LIMITED is a private limited company registered in England and Wales since its incorporation on 26 January 2000 and remains active on the register. It has changed its name 2 times, most recently from IMMUNOCLIN LABORATORIES LIMITED on 22 June 2000. Its registered office is at 2 Royal College Street, London, NW1 0NH. Its principal activities are manufacture of pharmaceutical preparations (SIC 21200), technical testing and analysis (SIC 71200) and research and experimental development on biotechnology (SIC 72110).
It is controlled by Dr Dorothy H Bray, which holds 75-100% of the shares. The board consists of two British directors: BRAY, Dorothy Helen, Dr (appointed 10 December 2002) and BRAY, Jonathan Leslie (appointed 4 October 2013). BRAY, Jonathan Leslie serves as company secretary (appointed 10 December 2002). The company has been served by five former officers who have since resigned. One person with significant control is recorded as having ceased.
Its regulatory record is clean, with no charges, no insolvency proceedings and no liquidation history. The company filed its most recent micro-entity accounts, covering the period to 28 February 2025, on 17 November 2025. The next accounts are due by 30 November 2026. Its most recent confirmation statement was made up to 16 July 2026. The next is due by 30 July 2027. 92 filings are recorded against the company at Companies House, most recently a confirmation statement filing on 16 July 2026.
Compliance
Financial snapshot
Year ended 28 February 2025| Year ended | Fixed assets | Current assets | Net assets/liabilities | Change |
|---|---|---|---|---|
| 28 Feb 2025 | £40,388 | £19,768 | -£226,364 | ▼-£15,972 |
| 29 Feb 2024 | £50,486 | £85,128 | -£210,392 | ▲+£32,863 |
| 28 Feb 2023 | £5,545 | £46,348 | -£243,255 | — |
| — | — | — | — | — |
| — | — | — | — | — |
| — | — | — | — | — |
| — | — | — | — | — |
Capital table
Updated on 19 September 2026- DOROTHY H BRAY (100.0%)
Share classes
| Class | Allocated shares | Currency | Nominal value | Voting | Dividend | Transfer | Anti-dilution |
|---|---|---|---|---|---|---|---|
| ORDINARY | 10,000,000 | — | — | ||||
| Total | 10,000,000 | ||||||
Shareholders
| Shareholder | Share class | Shares | Shareholding | Votes | Voting |
|---|---|---|---|---|---|
| DOROTHY H BRAY | ORDINARY | 10,000,000 | 100.00% | 10,000,000 | 100.00% |
| Total | 10,000,000 | 100% | 10,000,000 | 100% |
Officers
Persons with significant control
Funding
0 funding roundsNo funding rounds on record.
Filing history
No filings match this type.
Risk at a glance
- Company active
- Accounts up to date
- Confirmation statement up to date
- No insolvency history
- No registered charges
- Credit score
- Recommended limit
- Payment risk
Get the complete credit report
- Detailed financial statements
- Credit score & payment risk
- CCJs, charges & insolvency checks
- Recommended credit limit
Secure checkout · Report delivered instantly
Related companies
Sharing officers with this company